Metabolically Supported Chemotherapy (MSCT) is based on the Warburg hypothesis; a phenomenon also referred to as the “Warburg effect”. Otto Warburg conducted the research that brought about this hypothesis, in 1924. Warburg recognized that cancer cells metabolize glucose in a manner that is distinct from that of cells in normal tissue.
In contrast to the widely accepted gene oriented view on the development of cancer, which supports the proposition that the origins of cancer are genetic and that cancer primarily results from dynamic changes in the genome, the Warburg hypothesis, in its simplest form, asserts that cancer is primarily a disease of metabolic dysregulation. Metabolically Supported Chemotherapy (MSCT) is centered on various types of metabolic interventions targeting the metabolic dysregulation of cancer cells.
Metabolically Supported Chemotherapy (MSCT) is our own modified and improved method of Insulin Potentiated Chemotherapy (IPT) and is the main method that we use to increase the effectiveness of conventional therapeutics.
With this method, we can use smaller doses of cytotoxics and can deliver at the same time a higher concentration of them to the cancerous tissue. Overall, it improves treatment results and also reduces potentially serious side effects.